EP News: Allied Professionals
In this non-prespecified, post hoc analysis of the AUGUSTUS (The Open-Label, 2 x 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention) trial (Harskamp et al. J Am Coll Cardiol. 2022;79:417-27. PMID-35115097), the authors sought to evaluate whether the risk of bleeding or stroke as assessed by baseline HAS-BLED and CHA2DS2-VASc scores affected the results of the trial.
Source: Heart Rhythm - Category: Cardiology Authors: Erica S. Zado Source Type: research
More News: Angioplasty | Aspirin | Atrial Fibrillation | Bleeding | Cardiology | Clinical Trials | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Stroke | Vitamin K | Vitamins